Tag Archives: Senseonics

Tandem, Amarin, and Intercept Q2 ’22 Earnings Updates; Anthem to Cover Eversense E3 Implantable CGM

A series of cardiometabolic-related news items have been observed: Tandem (press release), Amarin (press release; slides), and Intercept (press release; slides) hosted their respective earnings calls; and Senseonics announced Anthem is now covering implantable CGMs, including Senseonics’s Eversense E3 CGM. Below, FENIX provides highlights and insights for the respective new items.

This content is for Read Less members only.
Register
Already a member? Log in here

Senseonics Eversense E3 CGM Receives CE Mark; Tandem Appoints Two New Members to Board of Directors; Akero Announces Financing Transactions with Pfizer and Hercules Capital

Three cardiometabolic-related news items have been observed: Senseonics announced it has received CE Mark for the next-generation Eversense E3 CGM system; Tandem announced the appointment of two new directors to its board; and Akero Therapeutics announced two financing transactions with Pfizer and Hercules Capital. Below, FENIX provides highlights and insights for the respective new items.

This content is for Read Less members only.
Register
Already a member? Log in here

Senseonics, Viatris, and Bayer Q1 ’22 Earnings Updates; Novo and Flagship Pioneering Collaboration; First Patient Dosed in Adocia Ph3 BC Lispro Trial

A series of cardiometabolic-related news items have been observed: Senseonics hosted its Q1 ‘22 earnings call (press release); Novo Nordisk announced a strategic collaboration with Flagship Pioneering for the development of novel research programs in cardiometabolic and rare diseases; Viatris (press release; slides) and Bayer (press release; slides) hosted their respective Q1 ’22 earnings calls; and Adocia announced the first patient has been dosed in its Ph3 BC Lispro program being conducted by partner Tonghua Dongbao (THDB). Below, FENIX provides highlights and insights for the respective new items.

This content is for Read Less members only.
Register
Already a member? Log in here

Jardiance EMPULSE Trial Published; Senseonics Q4 ’21 Earnings Update; Novo Initiates Icosema COMBINE 2 Ph3 Trial; Merck’s Oral PCSK9i Enters Ph2; BI Partners with Lifebit; Intercept and Amarin Q4 ’21 Earnings Updates

A series of cardiometabolic-related news items have been observed from BI/Lilly, Senseonics, Novo, Merck, BI/Lifebit, Intercept, and Amarin. Below, FENIX provides highlights and insights for the respective new items.

This content is for Read Less members only.
Register
Already a member? Log in here

Will AZ Fund an Additional Roxa Trial?; Senseonics Eversense E3 CGM Receives FDA Approval

Two cardiometabolic-related news items have been observed: AZ’s Executive VP and head of biopharmaceuticals R&D conducted an interview and commented on the likelihood of performing another roxadustat trial to address the FDA CRL (view article); and Senseonics announced its Eversense E3 CGM (180-day sensor) has received FDA approval. Below, FENIX provides highlights and insights for the respective new items.

This content is for Read Less members only.
Register
Already a member? Log in here

Senseonics Announces FDA Review for 180-day CGM Nearing Completion; Alnylam and Novartis Announce Collaboration for Liver Failure

Two cardiometabolic-related news items have recently been observed: Senseonics announced updates to its business, including an anticipated PMA supplement approval for its Eversense 180-day CGM “in the coming weeks”; and Alnylam and Novartis announced an exclusive three-year research collaboration to develop an siRNA-based targeted therapy for end-stage liver diseases. Below, FENIX provides highlights and insights for the respective new items.

This content is for Read Less members only.
Register
Already a member? Log in here

Bayer and Senseonics Q3 ’21 Earnings Updates; Abbott and ADA Launch Community Initiative; Provention Bio Launches #Type1TestedPledge Campaign; Beyond Type 1 Receives $750,000 Grant

A series of cardiometabolic-related news items have been observed: Bayer (press release; slides) and Senseonics (press release) hosted their respective Q3 ’21 earnings calls; Abbott and the American Diabetes Association (ADA) announced the launch of their first joint community initiative in Columbus, Ohio; Provention Bio announced the launch of its #Type1TestedPledge Campaign for Diabetes Awareness Month; and Beyond Type 1 announced it has received a $750,000 Grant from the Helmsley Charitable Trust. Below, FENIX highlights and insights for the respective new items.

This content is for Read Less members only.
Register
Already a member? Log in here

ADA 2021 Key Press Releases (June 28)

On day four of ADA 2021, eight cardiometabolic-related news items were observed from Bigfoot, AZ, Mannkind, Medtronic, Senseonics, BI/Lilly, Sanofi, and REMD Biotherapeutics. Below, FENIX provides context and analysis for the announcements, including thoughts on how the ALT increases observed in REMD’s Ph2 volagidemab trial could spell disaster in Ph3.

This content is for Read Less members only.
Register
Already a member? Log in here

Senseonics Q4 ’20 Earnings Update; Provention Bio Extended Follow-up Data Published; Voluntis Collaborates with Zendesk for Global Customer Support

A series of diabetes-related news items have been observed: Senseonics hosted its Q4 and FY ’20 earnings call; Provention Bio announced the extended follow-up data from the pivotal “At-Risk” TN-10 Study has been published in Science Translational Medicine; and Voluntis announced a collaboration with Zendesk to upgrade its global customer support infrastructure. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here